ArticleWorld journal of gastroenterology2017
Current and emerging pharmacological therapy for non-alcoholic fatty liver disease.
Article in World journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 51 citations in OpenAlex.
- The immunometabolic mechanisms and therapeutic targets of metabolic dysfunction-associated steatohepatitis.Frontiers in medicine · 2026Review
- Nanomedicine Strategies Utilizing Lipid-Based Nanoparticles for Liver Cancer Therapy: Exploring Signaling Pathways and Therapeutic Modalities.Advanced pharmaceutical bulletin · 2024Review
- Bile acids and coronavirus disease 2019.Acta pharmaceutica Sinica. B · 2024Review
- Angiotensin receptor blockers might be protective against hepatic steatosis after liver transplantation.BMC gastroenterology · 2023Article
- NAFLD and nutraceuticals: a review of completed phase III and IV clinical trials.Frontiers in medicine · 2023Review
- A Novel 2-Hit Zebrafish Model to Study Early Pathogenesis of Non-Alcoholic Fatty Liver Disease.Biomedicines · 2022Article
- Beneficial Activities ofNutrients · 2022Article
- Identification of hepatic fibrosis inhibitors through morphometry analysis of a hepatic multicellular spheroids model.Scientific reports · 2021Article
- Pentoxifylline with metformin treatment improves biochemical parameters in patients with nonalcoholic steatohepatitis.Journal of medical biochemistry · 2020Article
- Observational
- Rapamycin-Loaded mPEG-PLGA Nanoparticles Ameliorate Hepatic Steatosis and Liver Injury in Non-alcoholic Fatty Liver Disease.Frontiers in chemistry · 2020Article
- Obesity-Induced Upregulation of ZBTB7A Promotes Lipid Accumulation through SREBP1.BioMed research international · 2020Article
- Article
- Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges.Digestive diseases and sciences · 2019Review
- Folate receptor-beta expression as a diagnostic target in human & rodent nonalcoholic steatohepatitis.Toxicology and applied pharmacology · 2019Article
- Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.World journal of gastroenterology · 2019Review
- Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children: where do we stand?Current opinion in clinical nutrition and metabolic care · 2019Review
- RAGE is a Potential Cause of Onset and Progression of Nonalcoholic Fatty Liver Disease.International journal of endocrinology · 2019Review
- Simvastatin Reduces Hepatic Oxidative Stress and Endoplasmic Reticulum Stress in Nonalcoholic Steatohepatitis Experimental Model.Oxidative medicine and cellular longevity · 2019Article
- Staging systems of hepatocellular carcinoma: A review.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The main treatment of patients with non-alcoholic fatty liver disease (NAFLD) is life style modification including weight reduction and dietary regimen. Majority of patients are safely treated with this management and pharmacologic interventions are not recommended. However, a subgroup of NAFLD patients with non-alcoholic steatohepatitis (NASH) who cannot achieve goals of life style modification may need pharmacological therapy. One major obstacle is measurement of histological outcome by liver biopsy which is an invasive method and is not recommended routinely in these patients. Several medications, mainly targeting baseline mechanism of NAFLD, have been investigated in clinical trials for treatment of NASH with promising results. At present, only pioglitazone acting as insulin sensitizing agent and vitamin E as an anti-oxidant have been recommended for treatment of NASH by international guidelines. Lipid lowering agents including statins and fibrates, pentoxifylline, angiotensin receptor blockers, ursodeoxycholic acid, probiotics and synbiotics are current agents with beneficial effects for treatment of NASH but have not been approved yet. Several emerging medications are in development for treatment of NASH. Obeticholic acid, liraglutide, elafibranor, cenicriviroc and aramchol have been tested in clinical trials or are completing trials. Here in, current and upcoming medications with promising results in clinical trial for treatment of NAFLD were reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.